Joel Ackerman
Management
Good morning. I’m Joel Ackerman, the CEO of Champions Oncology. Thank you for joining us for our quarterly earnings call. As always I will start with the highlights since our last call, discuss the financial results, and then open up the call for questions. Before I start, I will remind you that I will make forward-looking statements during the call and actual results could differ materially from what is described in those statements. Additional information on factors that could cause results to differ is available in our Forms 10-Q and 10-K. Reconciliation of the non-GAAP financial measures that maybe discussed on the call to GAAP financial measures is available in the earnings release. Clearly the major event since our last call was financing. As you probably know, we raised $14 million last week. This is the third and largest round of capital that Ronnie and I have raised since we joined the company in 2010. We started the process in the early fall with the goal of raising at least $10 million. Overall the feedback about the company was positive. There was broad recognition of the magnitude of the problems in oncology for both drug development and clinical care. Investors appreciated the size of the potential markets we are pursuing and the unique strategy that we have. Well, I am definitely biased, we also got good marks on the quality of the management team we have assembled. Investors were also impressed by the strong support from current investors including myself and Ronnie Morris, the company's President and our continued participation as investors in the company. The $14 million round was led by New Enterprise Associates or NEA, one of the world's largest and most active venture capital firms. NEA has deep domain expertise in healthcare. Included in their portfolio was…